[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-368473-105":59,"doc-detail-368473-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","the-persistent-risk-of-secondary-malignancies-in-gastric-neuroendocrine-tumor-survivors-a-population-based-analysis","The persistent risk of secondary malignancies in gastric neuroendocrine tumor survivors - a population-based analysis","","Gastric neuroendocrine tumors (G-NETs) are rare with favorable survival, yet survivors face a substantial risk of developing second primary malignancies (SPMs). This population-based analysis estimates relative SPM risks in G-NET survivors and evaluates how risk varies by patient age, sex, race, latency period, marital status, and surgical intervention. Using SEER data from 2000–2021, it calculates standardized incidence ratios and excess absolute risks. Among 5,072 survivors, 912 (18.0%) developed SPMs with a median 34.3-month interval, showing persistently elevated risk, strongest within 4 years post-diagnosis.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-persistent-risk-of-secondary-malignancies-in-gastric-neuroendocrine-tumor-survivors-a-population-based-analysis/368473/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-persistent-risk-of-secondary-malignancies-in-gastric-neuroendocrine-tumor-survivors-a-population-based-analysis/368473.png","ImageObject",300,407,{"name":92,"@type":93},"Sophia Brooks","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",14,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is the study aiming to estimate in gastric neuroendocrine tumor survivors?","Question",{"text":113,"@type":114},"To estimate relative risks of second primary malignancies (SPMs) in G-NET survivors and examine variation across key patient characteristics such as age, sex, race, latency, marital status, and surgical intervention.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Which data source and time range are used to analyze SPM risk?",{"text":118,"@type":114},"The analysis uses the Surveillance, Epidemiology, and End Results (SEER) database (November 2023 submission), covering cases diagnosed from 2000 to 2021.",{"name":120,"@type":111,"acceptedAnswer":121},"When is the SPM risk highest after a G-NET diagnosis?",{"text":122,"@type":114},"The highest SPM risk occurs within the first 4 years after G-NET diagnosis, followed by a gradual decline.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},368473,1790216018,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},962084925636,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Clinical and Experimental Medicine (2025) 25:158 [https://doi.org/10.1007/s10238-025-01706-y](https://doi.org/10.1007/s10238-025-01706-y)  \nThe persistent risk of secondary malignancies in gastric neuroendocrine tumor survivors: a population‑based analysis  \nYuheng Ding3 · Jun Liu1,2 · Lingna Shen1,2 · Zhipeng Yan1,2 · Yonghong Huang1,2 · Yihui Huang1,2 · Rong Huang1,2 · Yunda Qian1,2 · Xiaojun Lou1,2 · Lai Wang1,2  \nReceived: 18 January 2025 / Accepted: 20 April 2025 / Published online: 14 May 2025 © The Author(s) 2025  \nAbstract  \nGastric neuroendocrine tumors (G-NETs) are rare neoplasms with a favorable survival rate, yet they present a significant risk for second primary malignancies (SPMs) . This study aims to estimate the relative risks of SPMs in G-NET survivors, exploring variations across key patient characteristics. Patients diagnosed with G-NETs were identified from the Surveillance, Epidemiology, and End Results database (2000–2021) . Standardized incidence ratios (SIRs) and excess absolute risks (EARs) were calculated to assess SPM risk stratified by age at diagnosis, gender, race, latency period, marital status, and surgical intervention. Among 5072 G-NET survivors, 912 (18.0%) developed SPMs, with a median interval of 34.3 months between the diagnoses. The overall SIR for SPMs was 2.09 (95% confidence interval [CI] 1.96–2.23), corresponding to an EAR of 145.64 per 10,000 person-years. Increased risks were observed for cancers of the stomach, small intestine, thyroid, hepatobiliary system, pancreas, and esophagus. The highest risk for SPMs occurred within the first 4 years following G-NET diagnosis (SIR 2.57; 95% CI 2.11–3.1), with a gradual decline thereafter. Patients under 50 years had the highest SIRs, particularly for stomach cancer (SIR 196.28; 95% CI 160.21–238.05). Females exhibited a slightly higher SIR than males. White patients demonstrated the highest risk for stomach cancer, with an SIR of 63.88 (95% CI 57.00–71.38) . G-NET survivors are at a persistently elevated risk of developing SPMs, particularly within the first 4 years of diagnosis. Age, gender, and racial factors significantly influence this risk. Personalized surveillance strategies are warranted to address these disparities and reduce SPM incidence.  \nKeywords Gastric neuroendocrine tumors · Second primary malignancy · Risk factors · Standardized incidence ratios  \nIntroduction  \nGastric neuroendocrine tumors (G-NETs) are a rare and distinct category of neoplasms that originate from the enterochromaffin-like cells within the gastric mucosa [1–3] . In recent decades, advances in early detection and treatment strategies have significantly improved the survival rates  \n* Lai Wang [czz7225883@126.com](czz7225883@126.com)  \n1 Department of Gastroenterology, Jiaxing Hospital of Traditional Chinese Medicine, Jiaxing 314000, Zhejiang, China  \n2 Department of Internal Medicine, Jiaxing University Affiliated TCM Hospital, Jiaxing 314000, Zhejiang, China  \n3 Hangzhou Institute of Medicine (HIM), Zhejiang Cancer Hospital, Chinese Academy of Sciences, Hangzhou 310022, Zhejiang, China  \nfor individuals diagnosed with G-NETs [4] . The evolving systemic treatment scenario for G-NETs encompasses significant advancements, including the use of somatostatin analogs (SSAs) for hormone control, peptide receptor radionuclide therapy (PRRT) for metastatic disease, and targeted therapies such as tyrosine kinase inhibitors (TKIs) and mTOR inhibitors. Additionally, emerging evidence suggests that immune checkpoint inhibitors (ICIs) and novel chemotherapy combinations may offer therapeutic benefits, particularly for high-grade or poorly differentiated G-NETs [5–9] . However, the long-term health outcomes for these survivors remain an important area of investigation. A critical concern is the heightened risk of developing second primary malignancies (SPMs), which poses an ongoing challenge for clinicians and researchers [10–13] .  \nThe clinical characteristics and risk","cbCaiix7WLDtihYu","https://ap.wps.com/l/cbCaiix7WLDtihYu","pdf",1004558,11,"English","# Abstract\n# Introduction\n# Material and methods\n## Data source","[{\"question\":\"What is the study aiming to estimate in gastric neuroendocrine tumor survivors?\",\"answer\":\"To estimate relative risks of second primary malignancies (SPMs) in G-NET survivors and examine variation across key patient characteristics such as age, sex, race, latency, marital status, and surgical intervention.\"},{\"question\":\"Which data source and time range are used to analyze SPM risk?\",\"answer\":\"The analysis uses the Surveillance, Epidemiology, and End Results (SEER) database (November 2023 submission), covering cases diagnosed from 2000 to 2021.\"},{\"question\":\"When is the SPM risk highest after a G-NET diagnosis?\",\"answer\":\"The highest SPM risk occurs within the first 4 years after G-NET diagnosis, followed by a gradual decline.\"}]","The persistent risk of secondary malignancies in gastric neuroendocrine tumor survivors - a population-based analysis | PDF",1790177146,28,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1101ad557e2e3b3b2b60fbb8b97db496.webp",983,1305,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ffe578125aa4f6a5705a823a679db6c6.webp",982,1304,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a569b56c4a8b6fdaf86d1f6d9f40e72e.webp",981,1303,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ff21ebc30baa3105d826fbae9aa72ece.webp",980,1301]